Praxis Precision (PRAX) Medicines announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for ulixacaltamide, a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of patients with essential tremor
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Ulixacaltamide’s Commercial Edge and 2026 Pipeline Catalysts Drive Substantial Upside to $843 Target
- Praxis Precision price target raised to $843 from $507 at BTIG
- Praxis Precision price target raised to $750 from $250 at Oppenheimer
- Praxis Precision price target raised to $313 from $303 at Deutsche Bank
- Praxis Precision Medicines Plans New Drug Application